Utility of Sequencing the erm(41) Gene in Isolates of Mycobacterium abscessus subsp. abscessus with Low and Intermediate Clarithromycin MICs

ABSTRACT The erm(41) gene confers inducible macrolide resistance in Mycobacterium abscessus subsp. abscessus, calling into question the usefulness of macrolides for treating M. abscessus subsp. abscessus infections. With an extended incubation (14 days), isolates with MICs of ≥8 μg/ml are considered macrolide resistant by current CLSI guidelines. Our goals were to determine the incidence of macrolide susceptibility in U.S. isolates, the validity of currently accepted MIC breakpoints, and the erm(41) sequences associated with susceptibility. Of 349 isolates (excluding those with 23S rRNA gene mutations), 85 (24%) had clarithromycin MICs of ≤8 μg/ml. Sequencing of the erm(41) genes from these isolates, as well as from isolates with MICs of ≥16 μg/ml, including ATCC 19977T, revealed 10 sequevars. The sequence in ATCC 19977T was designated sequevar (type) 1; most macrolide-resistant isolates were of this type. Seven sequevars contained isolates with MICs of >16 μg/ml. The T28C substitution in erm(41), previously associated with macrolide susceptibility, was identified in 62 isolates (18%) comprising three sequevars, with MICs of ≤2 (80%), 4 (10%), and 8 (10%) μg/ml. No other nucleotide substitution was associated with macrolide susceptibility. We recommend that clarithromycin susceptibility breakpoints for M. abscessus subsp. abscessus be changed from ≤2 to ≤4 μg/ml and that isolates with an MIC of 8 μg/ml have repeat MIC testing or erm sequencing performed. Our studies suggest that macrolides are useful for treating approximately 20% of U.S. isolates of M. abscessus subsp. abscessus. Sequencing of the erm gene of M. abscessus subsp. abscessus will predict inducible macrolide susceptibility.

[1]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[2]  R. Wallace,,et al.  AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin. , 1998, Diagnostic microbiology and infectious disease.

[3]  J. Gaillard,et al.  Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm(41) and rrl Sequencing , 2010, Antimicrobial Agents and Chemotherapy.

[4]  R. Wallace,,et al.  Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus , 1996, Antimicrobial agents and chemotherapy.

[5]  R. Wallace,,et al.  PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria , 1995, Journal of clinical microbiology.

[6]  C. Fraser,et al.  High-level Relatedness among Mycobacterium abscessus subsp. massiliense Strains from Widely Separated Outbreaks , 2014, Emerging infectious diseases.

[7]  R. Wallace,,et al.  Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. , 1996, The Journal of infectious diseases.

[8]  R. Wallace,,et al.  Intrinsic Macrolide Resistance in Rapidly Growing Mycobacteria , 2006, Antimicrobial Agents and Chemotherapy.

[9]  R. Wallace,,et al.  A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae , 2008, Antimicrobial Agents and Chemotherapy.

[10]  T. Myers,et al.  New Rapid Scheme for Distinguishing the Subspecies of the Mycobacterium abscessus Group and Identifying Mycobacterium massiliense Isolates with Inducible Clarithromycin Resistance , 2013, Journal of Clinical Microbiology.

[11]  Frank,et al.  Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis , 1993, Journal of clinical microbiology.

[12]  R. Wallace,,et al.  Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare , 1994, Antimicrobial Agents and Chemotherapy.

[13]  Y. Kook,et al.  Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns , 2010, Microbiology and immunology.

[14]  Didier Raoult,et al.  rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. , 2006, International journal of systematic and evolutionary microbiology.

[15]  R. Wallace,,et al.  Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .